The IPO market for med-tech companies continues to set new records. With one IPO closed the last week of June, two slated for ...

Inmune Bio Inc. claimed a phase II win with TNF inhibitor Xpro (pegipanermin) in early Alzheimer’s disease (AD), though the ...

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product that the company has been ...

T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

B4, to its pipeline for prevention of group A Streptococcus (GAS) infections. Invasive GAS infections can cause diseases such ...

At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers ...

CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, ...

Aprea Therapeutics Inc. has announced new preclinical data on APR-1051, the company’s next-generation oral WEE1 inhibitor, in ...

Novo Nordisk A/S recently presented data regarding their antibody fragment Inno-8 for the potential treatment of hemophilia A ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

Mira Pharmaceuticals Inc. has reported new in vitro preclinical data supporting the therapeutic potential of SKNY-1, a ...

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...